KDNY Insider Trading Activity and SEC Form 4 Filings
KDNY insider trading summary
No open-market insider purchases or sales of Chinook Therapeutics, Inc. (KDNY) have been reported on SEC Form 4 in the past 12 months.
Latest KDNY insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 1, 2023 | Andrew James King | Chief Scientific Officer | Sell | $46K (1,168 @ $39.03) |
| May 30, 2023 | William Mariner Greenman | Director | Sell | $27K (1,155 @ $23.30) |
| Apr 24, 2023 | Eric Dobmeier | President, CEO | Sell | $514K (23,800 @ $21.58) |
| Apr 24, 2023 | Eric Dobmeier | President, CEO | Sell | $27K (1,200 @ $22.26) |
| Apr 17, 2023 | Davis Jerel | Director | Sell | $6.1M (295,808 @ $20.75) |
| Apr 4, 2023 | Mahesh Krishnan | Director | Sell | $21K (924 @ $23.01) |
| Apr 3, 2023 | Andrew James King | Chief Scientific Officer | Sell | $117K (5,000 @ $23.34) |
| Mar 1, 2023 | Davis Jerel | Director | Sell | $5.5M (240,000 @ $22.75) |
| Mar 1, 2023 | Davis Jerel | Director | Sell | $2.8M (123,249 @ $22.75) |
| Mar 1, 2023 | Davis Jerel | Director | Sell | $836K (36,751 @ $22.75) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.